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Increased levels of circulating endothelial cells in chronic pe-
riaortitis as a marker of active disease.
Background. The pathogenesis of chronic periaortitis (CP)
has not been clarified. The histologic features and the associ-
ation with autoimmune diseases suggest an immune-mediated
disorder with marked inflammatory vascular and perivascular
lesions. To clarify the role of vascular damage we looked for the
presence and the surface phenotype of circulating endothelial
cells (CECs) in the peripheral blood of patients with chronic
periaortitis.
Methods. Eleven patients with CP were evaluated for the
presence of CECs; 9 patients had active and 2 inactive disease.
Three patients with active disease were also evaluated 3 months
after therapy. Ten atherosclerotic patients, 10 patients with renal
insufficiency of variable degree and etiology, and 40 healthy sub-
jects were evaluated as controls. Five-parameter, 3-color flow
cytometry was performed with a FACScan. CECs were defined
as CD45 negative, CD31, P1H12, and CD36 positive, and acti-
vated CECs as CD45 negative and P1H12, CD62 positive.
Results. The median number of CECs in patients with CP
(106 cells/mL) was significantly higher than in healthy con-
trols (16 cells/mL, P = 0.0004) and atherosclerotic patients
(25 cells/mL, P = 0.0005) Two patients with inactive disease
had a CEC count comparable to that of normal subjects. In 2 of
the 3 patients reevaluated, 3 months after therapy CEC num-
bers normalized. Almost all CECs were microvascular in origin
and showed an activated phenotype.
Conclusion. The presence of a high number of CECs in the
active phase of chronic periaortitis and their normalization dur-
ing inactive disease suggest that endothelial damage may play
a role in the pathogenesis of the disease.
The term chronic periaortitis (CP) refers to a family
of inflammatory diseases with similar morphologic ap-
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pearance, namely idiopathic retroperitoneal fibrosis, pe-
rianeurysmal retroperitoneal fibrosis, and inflammatory
aneurysm of the aorta [1]. The clinical presentation may
be different according to the anatomic location. When
the ureter is involved, pain in the low back region is
common, and may be associated with low-grade fever
and weight loss. An obstructive uropathy usually devel-
ops, which may remain asymptomatic until it leads to re-
nal insufficiency. Arterial invasion with aortic aneurysm,
or portal hypertension and/or bile duct obstruction with
pseudotumor of pancreas, as well as extrinsic venous com-
pression with deep venous thrombophlebitis of legs, may
also occur. Ultrasonography may show hydronephrosis
and intravenous urography may show a medial devia-
tion of the ureter in the case of retroperitoneal fibrosis.
However, the identification of the retroperitoneal mass is
made by computed tomography or magnetic resonance.
Once the mass has been identified the main problem is the
differential diagnosis between CP and a retroperitoneal
tumor. Laparatomy and multiple deep biopsies are re-
quired to ascertain the diagnosis. Surgical treatment with
blunt dissection can be successful, but in many cases fibro-
sis recurs months or years later. Steroid therapy is often
used either as primary therapy or in adjunct to surgery.
Immunosuppressive agents and tamoxifen may also be
helpful [2].
The diseases classified as CP have in common the
histopathologic characteristics of severe adventitial
and perivascular inflammatory infiltrate, which evolves
throughout fibrosis around atherosclerotic vessels. Be-
cause of these histologic features, CP has been classified
among the scleroderma like disorders [3]. The patho-
genesis of CP remains unknown. However, the reported
association of CP with vasculitic syndromes [4] or au-
toimmune diseases [5–7], and the positivity of antinuclear
antibodies (ANA) and anti-neutrophil cytoplasmic anti-
bodies (ANCA) in a few patients with CP [8–11], may
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suggest a role for immunologic mechanisms in the patho-
genesis of the disease.
In the present study, we assessed by cytometric method
the presence and the surface phenotype of circulating
endothelial cells in patients with CP. We also evaluated
whether the presence of CECs is associated with the ac-
tive phase of the disease and can be used as a marker of
the immune-mediated vessel damage.
METHODS
Patients and controls
Patients with a diagnosis of chronic periaortitis based
on computed tomography (CT) were selected for this
study. An informed consent was given by all patients. At
the moment of investigation, none of the patients were
taking any medication potentially responsible for chronic
periaortitis. Infection and malignancy were excluded on
clinical and laboratory grounds, and with a histologic
evaluation in 7 out of 11 patients. Five histologic sam-
ples were obtained during surgery and 2 by laparoscopy.
The following definitions were adopted: (1) “active dis-
ease,” characterized by the presence of a periaortic mass
englobing 1 or both ureters with hydronephrosis at CT
scan plus an increase in C-reactive protein (CRP) and/or
erythrocyte sedimentation rate (ESR); (2) “inactive dis-
ease,” characterized by the regression of hydronephrosis,
and by a marked reduction of fibrotic tissue at CT scan
in comparison to the basal examination together with the
normalization of CRP and ESR; (3) “reactivation of the
disease,” when after at least 1 year of quiescence a control
CT scan showed a new increase of the periaortic mass en-
globing 1 or both ureters associated with a new increase
in CRP and/or ESR.
The clinical and laboratory data collected for this study
are those obtained at the time the blood samples were
taken.
We used 3 groups of controls, patients with atheroscle-
rosis, patients with renal insufficiency, and normal sub-
jects. Ten patients (8 males and 2 females, median age of
64 years, range 54–78 years) with a history of atheroscle-
rotic vascular disease were examined as vascular disease
controls. Three out of 10 patients had atherosclerotic
coronary artery disease, 4 had femoral atherosclerosis
with claudication in 2, and 4 had carotid stenosis. A com-
puted tomography was done on all these patients to ex-
clude the presence of chronic periaortitis. Ten patients (7
males and 3 females, median age of 66 years, range 36–74
years) with renal insufficiency of variable degree (median
plasma creatinine 4.5 mg/dL range 1.6-9 mg/dL) and eti-
ology (chronic interstitial nephritis 3 patients, nephroan-
giosclerosis 3 patients, diabetic nephropathy 2 patients,
polycystic kidney disease 2 patients) were used as con-
trols with renal insufficiency. Forty sex- and age-matched
healthy subjects were investigated as normal controls.
Autoantibody profile
ANA and anti-dsDNA antibodies were assessed by
indirect immunofluorescence using Hep-2 cells and
Chritidia lucilliae, respectively. Antiextractable nuclear
antigen antibodies were measured by enzyme-linked im-
munoabsorbent assay (ELISA) (Diamedix, Miami, FL,
USA). ANCA were detected by indirect immunofluo-
rescence on fixed neutrophils and by ELISA using pro-
teinase 3 and myeloperoxidase as antigens [12].
To assess whether sera from CP patients displayed
the same reactivity against endothelial cells (EC) ob-
tained from different human anatomic sources, we eval-
uated the AECA activity of CP sera against large arte-
rial (aorta) and microvascular EC. AECA were detected
using a cell surface ELISA on macrovascular (human
aortic endothelial cells) and microvascular (human
dermal-derived endothelial cells, d-HMEC) confluent liv-
ing endothelial cells, as previously described [13]. All
the above-described parameters were measured in each
patient.
Detection of CECs by flow-cytometry analysis
Circulating endothelial cells were detected directly on
whole peripheral blood by flow cytometry, as previously
described [14]. Briefly, 200 lL of peripheral blood sam-
ples in sodium heparin was labeled with 10 lL of a panel
of fluorescein isothiocyanate (FITC), R-phycoerythrin
(PE), or peridin chlorophyll protein (PerCP)-conjugated
antibodies anti-CD45, -CD31, -CD62, -CD36, and
-P1H12 for 20 minutes at room temperature. After conju-
gation, red blood cells were lysed by incubating in FACS
lysing solution (Becton Dickinson, San Jose, CA, USA)
for 15 minutes at room temperature. White blood cell
pellets were then washed twice in FACS flow solution
(Becton Dickinson).
Appropriate analysis gates, designed to remove dead
cells, platelet aggregates, and debris, and to exclude
CD45+ hematopoietic cells, were used to enumerate to-
tal and activated CECs. CECs were defined as CD45-
negative and CD31-, P1H12-, and CD36-positive [14].
Activated CECs were defined as P1H12- and CD62-
positive. Five-parameter, 3-color flow cytometry was per-
formed with a FACScan flow cytometer with a 15-mW
argon laser (excitation at 488 mm) (Becton Dickinson).
The sensitivity of fluorescence detectors was set and mon-
itored using Calibrite Beads (Becton Dickinson) accord-
ing to the manufacturer’s recommendations. A vial with
cells stained with IgG1 isotypic controls labeled with
FITC or PE was used as negative control. At least 100,000
(usually 300,000) cells per sample were acquired, and
analyses were considered informative when adequate
numbers of events (>100) were collected in the CEC enu-
meration gates [13]. Data were analyzed with CellQuest
software (Becton Dickinson).
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Table 1. Clinical characteristics at time of CECs determination
Ureteral Serum
PTS Sex AGE Diagnosis involvement creat mg/dL CRP ESR Auto-Abs AVD
1a F 60 IRPF Left right 10 0.5 60 Anti-thyroid pos
2a F 51 IRPF Left right 3.8 54 Anti-thyroid pos Femoral
3a M 65 IRPF Left 0.9 120 86 ANA pos
4a M 69 IRPF Left right 1.7 1.5 22 ANA pos
5a M 64 IRPF Right 1.98 2 30 Anti-thyroid pos Carotid
6b M 72 IRPF Right 1.4 1.4 62 Femoral
7b M 65 IRPF Right 1.6 7.7 70 AECA pos
8b M 63 Inflam A Right 4 1.5 40 Anti-thyroid pos
9b M 48 IRPF Left 1 7.6 15 Coronary
10c F 58 IRPF Left, right 1.4 0.1 7
11c M 76 IRPF Left, right 3.2 0.2 12 AECA pos
5d M 64 IRPF Right 1.1 0.2 11 Anti-thyroid pos Carotid
6d M 72 IRPF Right 1.0 0.1 15 Femoral
7d M 65 IRPF Right 1.2 0.4 10
Abbreviations are: M, male; F, female; IRPF, idiophatic retroperitoneal fibrosis; Inflam A, inflammatory aneurysm; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; Auto Ab, autoantibodies; Anti thyroid, antimicrosome and antithyreoglobulin antibodies; AECA, antiendothelial cells antibodies; AVD,
atherosclerotic vascular disease.
aPatients evaluated at diagnosis of chronic periaortitis; bpatients evaluated at reactivation of the disease; cpatients with inactive disease; dpatients reevaluated three
months after therapy.
The concentration of CECs per mL blood was calcu-
lated according the following formula: (e/m) × WBC ×
1000, where e is the number of CECs detected in the
CD45-negative enumeration gate; mis the total number
of cells acquired per sample, and WBC is the number of
circulating white blood cells per microliter.
Detection of soluble interleukin-6 (IL-6)
Plasma concentrations of IL-6 were assessed by ELISA
(R&D Systems, Minneapolis, MN, USA), and calculated
using a standard curve generated with specific standards.
Statistical analysis
Comparisons of CEC levels between CP patients, and
patients with diffuse atherosclerosis and healthy controls
were performed by the Mann-Whitney rank sum test. A
P value < 0.05 was considered significant. In addition, cor-
relations between CEC number and different CP disease
parameters were assessed by Spearman’s rank correla-
tion test.
RESULTS
Demographic and clinical features of patients
The study cohort consisted of 9 men and 2 women, with
a median age of 61 years (range 46–72 years). Ten patients
had a diagnosis of idiopathic retroperitoneal fibrosis, and
1 patient had a diagnosis of inflammatory aneurysm of
the aorta. The CT diagnosis rested on the demonstration
of a periaortic soft tissue mass of variable thickness that
enveloped the aorta and inferior vena cava between the
renal hilar and sacral promontory and extended laterally
to entrap the ureters, resulting in variable degrees of hy-
dronephrosis in 10 cases, and associated with an aneurysm
of the involved aorta in 1 case. At the time of diagno-
sis all patients had ureteral obstruction with unilateral
hydronephrosis in 2 and bilateral hydronephrosis in the
other 9. The latter 9 patients had impaired renal function
(median plasma creatinine 2.2 mg/dL, 25th to 75th per-
centile 1.8-8.5 mg/dL). Three out of the 11 patients had
deep vein thrombosis of the leg. Nine patients had an
elevated ESR (median 40 mm/h; 25th to 75th percentile:
16.75-61.5), and 7 had an elevated CRP (median 6 mg/dL;
25th to 75th percentile: 2-29 mg/dL; normal value <0.5
mg/dL). Five patients were submitted to ureterolysis and
transposition of the ureters with surgical repair of the
abdominal aortic aneurysm in 1 of them. During surgery,
multiple deep biopsies of the retroperitoneum were done.
Two other patients were submitted to laparoscopy with
multiple biopsies of the fibrotic mass. In the remaining
4 patients, the histologic evaluation of the fibrotic mass
was not done. The CT did not show any sign of malig-
nancy namely: a cranial location of the mass, anterior
displacement of the aorta, lateral displacement of the
ureters, and/or bone destruction [15]. These 4 patients
were treated with steroids with marked reduction of the
fibrotic mass and resolution of the hydronephrosis. They
were followed in our unit from 24 to 43 months after the
diagnosis of periaortic fibrosis without any sign of malig-
nancy.
At the time of CEC determination, 9 patients had clear-
cut evidence of active disease. Five of these 9 patients
were studied at the moment of diagnosis of CP, and 4
during a reactivation of the disease 3.5 ± 3.5 years af-
ter the diagnosis (Table 1). The other 2 patients had in-
active disease, respectively, 2 and 5 years after surgical
and steroid treatment. Four patients had an associated
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Fig. 1. Flow cytometry evaluation of circulating endothelial cells (CECs). (A) Representative panel showing the analysis gate used to exclude
platelets and debris (left), and the gate used to exclude CD45-positive hematopoietic cells (right). (B) Representative panels showing the negative
control, total, and microvascular CECs in chronic periaortitis. PerCP, peridin chlorophyll protein; PE, phycoerythrin; FITC, fluorescein isothio-
cyanate.
atherosclerotic vascular disease, namely: femoral steno-
sis in 2 patients, carotid stenosis in 1 patient, coronary
artery disease in 1 patient.
Three out of the 9 patients, first evaluated during active
disease, had a second evaluation 3 months after beginning
a treatment with steroids, and tamoxifen in 2 patients, and
steroids and mycophenolate mofetil in the last patient.
Autoantibodies
Four patients had thyroid dysfunction with antithy-
roid microsome and antithyreoglobulin antibodies. As
a consequence, 2 patients had hyperthyroidism and 2
had hypothyroidism. Two patients were ANA-positive
with speckled pattern. Cryoglobulins, rheumatoid factors,
ANCA, antibodies to ENA, and dsDNA were negative
in all patients. Two patients were positive for AECA-IgG
both on aorta and microvascular EC, at low titers.
CEC levels by flow-cytometry analysis
Using flow-cytometry analysis, we identified CECs as
negative for hematopoietic marker CD45 and positive
for endothelial markers P1H12 and CD34 (Fig. 1). The
mean number of CECs in patients with CP (mean value
106/mL, 95% CI 70–143) was significantly higher than in
healthy controls (16/mL, 95% CI 9–23; P < 0.0004), in pa-
tients with diffuse atherosclerosis (25/mL, 95% CI 16–33;
P = 0.0005) as well as in patients with renal insufficiency
(mean value 15/mL, 95% CI 8–29; P = 0.005). There was
not any significant difference between healthy controls,
patients with atherosclerosis, and patients with renal in-
sufficiency. Interestingly, while the number of CECs was
significantly higher than controls in patients with active
disease (ranging from 90 to 242 cells/mL, median 108
cells/mL, mean 114 cells/mL, SD 46.2) (Fig. 2), the 2
patients in clinical remission had low CEC counts (31
and 37 cells/mL, respectively), comparable to those of
atherosclerotic and normal subjects (Fig. 2). In 2 out of 3
patients with active disease, cell numbers declined after
3 months of treatment (from 108 to 34 cells/mL and from
105 to 6 cells/mL, respectively. No change in CECs lev-
els was observed in the third patient before (90 cells/mL)
and after therapy (85 cells/mL), in spite of normalization
of C-reactive protein, erythrocyte sedimentation rate,
and improvement of abdominal computed tomography
(Fig. 3).
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Fig. 2. Levels of circulating endothelial cells (CECs) in peripheral
blood obtained from patients with active chronic periaortitis (CP),
healthy (HC), and atherosclerotic (ATS) controls. Data are shown as
box plots, with upper and lower quartiles (shaded areas) and medians
(horizontal lines within shaded areas). The number of CECs in CP pa-
tients was significantly higher when compared with those in controls.
∗∗P < 0.001.
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Fig. 3. Cell numbers during the course of immunosuppressive therapy
in patients with active disease.
Phenotype of circulating endothelial cells
Among the various types of endothelial cells, only mi-
crovascular endothelial cells express CD36. We used this
marker to identify the vascular origin of CECs in patients
with CP. Almost all CECs of patients with CP expressed
CD36. To evaluate the activated state, we analyzed CECs
for dual expression of P1H12 and molecules that are ex-
pressed on the endothelial surface upon activation. The
number of CECs with surface expression of E-selectin
(CD62) had increased in patients with CP in comparison
with healthy controls (P = 0.005) (Fig. 4). Activated CEC
number and phenotype were higher in patients with an
active disease than in patients in a steady state (P = 0.005,
data not shown). No correlation between activated CECs
counts and ESR or CRP was found.
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Fig. 4. The activated phenotype of CECs was defined by P1H12 and
CD62 surface expression. Data are shown as box plots, with upper and
lower quartiles (shaded areas) and medians (horizontal lines within
shaded areas). The number of activated CECs was markedly increased
in patients with CP in comparison with atherosclerotic (ATS) and
healthy (HC) controls. ∗P = 0.005.
Detection of plasma IL-6 levels
The mean (± SD) plasma concentration of IL-6 was
25.13 ± 20.1 pg/mL in CP patients, and 3.8 ± 3.7 in healthy
subjects (P < 0.0001) and 4.1 ± 2.7 in vascular controls
(P < 0.0001). No positive correlation was found between
CECs and IL-6 levels.
DISCUSSION
The pathogenesis of CP remains unknown. The asso-
ciation of the disease with other autoimmune disorders
[4–7, 16, 17], as well as the presence of serologic markers
of immune activation in a small number of CP patients [8–
11], suggests that CP could be an immune-mediated dis-
order with marked inflammatory vascular traits. The in-
trinsic mechanisms triggering the inflammatory processes
in the adventitial and periadventitial vasa vasorum of the
aorta are, at the moment, unknown. Parums et al [18]
postulated that the disease may be due to an immune re-
action to some components of atherosclerothic plaques
(i.e., ceroids), which are a complex of proteins and oxi-
dized LDL. This hypothesis has been partially confirmed
by the finding of antibodies directed against ceroid in the
sera of patients with CP. However, the same antibodies
have also been detected in the sera of healthy elderly
subjects and in patients with atherosclerosis [18, 19].
Recently, a significant number of CECs have been de-
tected in different diseases, such as acute coronary syn-
drome, sickle cell anemia, rickettsia and cytomegalovirus
infection, SLE, ANCA-associated small-vessel vasculitis,
Kawasaki disease, and SSc [14, 10–27]. In addition, in a
large group of patients with SLE, we found a number
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of CECs higher than in normal controls [28], but lower
with respect to that observed in patients with CP in the
present study (mean values in SLE patients 44.5/mL, 95%
CI 38.6–50.3). The cumulative significance of these stud-
ies supports the evidence that endothelial damage plays
a key role in the pathogenesis of these diseases. More-
over, it is of interest that CEC numbers varied according
to the severity of the endothelial lesions and was closely
correlated with the degree of disease activity [14, 25–27].
It is worth noting that there are different methods
used to measure CECs, none of which is standardized,
so that it is difficult to compare one method to the oth-
ers. The method we used is one of the most frequently
used in recent studies. Although not validated, it al-
lows reliable results in different disease groups to be
obtained [29].
In this study, we found that patients with CP had a
significantly increased number of CECs in comparison
to healthy subjects, patients with diffuse atherosclero-
sis, and patients with renal insufficiency of variable de-
gree and etiology. These data indicate that endothelial
injury, as part of immune-mediated inflammatory vascu-
lar damage, may play a role in the pathogenesis of CP.
Actually, there is growing evidence that CP belongs to
a family of inflammatory vascular diseases characterized
by marked adventitial and periadventitial infiltration by
lymphocytes, plasma cells, and macrophages, involving
abdominal aorta and retroperitoneal small vessels some-
times with clear vasculitic lesions [11, 30–32]. Due to
these histologic features and the subsequent evolution
of the inflammatory lesions to fibrosis, it has been pro-
posed to classify CP among the scleroderma-like disor-
ders [3]. As a matter of fact, SSc is a connective tissue
disease characterized by an early phase of inflammatory
microangiopathy followed by a large deposition of col-
lagen fibrils and, finally, evolution to diffuse fibrosis [33,
34] involving skin and visceral organs. Instead, the lo-
calization of CP is limited to the collagen tissue around
the abdominal aorta. Recently, CECs have been found in
high number in SSc, and their amount was strongly cor-
related with active vascular disease and plasma markers
of endothelial damage [14]. Our data would suggest that
these 2 diseases share not only the histologic features, but
also some pathogenetic mechanisms. As described in SSc,
CECs in patients with CP seem to be a good marker of
early microvascular damage, while their number decrease
during the inactive phases of the disease or after an ef-
fective treatment. Although in our series the number of
patients with active or quiescent disease was small, it is of
interest that in 2 patients with inactive CP for more than
2 years the levels of CECs were low and comparable to
controls. In the 3 patients tested before and 3 months after
treatment, the level of CECs normalized in 2. These find-
ings, together with the absence of a significant number
of CECs in patients with diffuse atherosclerosis, which
have been selected as vascular disease controls, seem to
confirm that CECs can be considered as reliable markers
of microvascular injury in CP.
As far as circulating endothelial phenotype is con-
cerned, we found that almost all CECs in patients with
CP are microvascular in origin, as defined by the marker
CD36 [22, 35]. This finding could further suggest that
vascular injury in CP takes its origin from vasa vasorum
rather than the aortic layers. In addition, some CECs in
patients with CP have an activated phenotype, as evi-
denced by the surface expression of E-selectin. More-
over, we found increased plasma concentrations of IL-6,
which is an important cytokine, having a crucial role as an
inflammatory mediator and modulating fibroblast prop-
erties [36, 37].
CONCLUSION
The present study shows that high counts of CECs are
detectable in the peripheral blood of patients with CP,
CECs are elevated in active phases of CP, and CEC levels
normalized in inactive phases of CP and after immuno-
suppressive treatment. These data suggest that endothe-
lial damage may play a key role in the pathogenesis of
CP, and that the amount of CECs in the blood is strictly
correlated with the activity of the disease. Further studies
are necessary to evaluate whether CECs may be used to
monitor the activity of CP.
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